Here are the company-reported quarterly testing numbers for Cologuard, rounded, along with notable events in Exact’s history:
Oct. 9, 2014: Exact Sciences launches Cologuard.
November 2014: The American Cancer Society lists Cologuard in its Colorectal Cancer Prevention and Early Detection Guidelines.
February 2015: Exact announces more than 4,000 tests were completed in fiscal year 2014.
March 2015: Exact enters into a co-promotion agreement with Ironwood Pharmaceuticals to promote Cologuard.
May 2015: Nearly 11,000 tests completed in the first quarter of 2015
July 2015: More than 21,000 tests completed in the second quarter of 2015
October 2015: 34,000 tests completed in the third quarter of 2015
February 2016: 38,000 tests completed for the quarter; more than 104,000 completed in 2015
May 2016: 40,000 tests completed in the quarter
June 2016: Cologuard is included in U.S. Preventive Services Task Force 2016 CRC screening recommendations on equal standing with other screening tests
July 2016: 54,000 tests completed during the quarter
October 2016: 68,000 tests completed for the quarter; Cologuard is included in 2017 Healthcare Effectiveness Data and Information Set quality measures for CRC screening
February 2017: 82,000 tests completed for the quarter; 244,000 completed in 2016
April 2017: 100,000 tests completed for the quarter; Cologuard is included in Medicare Advantage Star Ratings.
July 2017: 135,000 tests completed in the quarter
October 2017: 161,000 tests completed in the quarter
November 2017: Exact announces plans to expand testing laboratory, headquarters in Madison, Wis.
January 2018: 176,000 tests completed in the quarter; 571,000 completed in 2017
February 2018: Exact surpasses 1 million completed tests
March 2018: Exact hires Paul Limburg, MD, as co-chief medical officer, and Mark Stenhouse as president of Cologuard
April 2018: 186,000 tests completed during the quarter
August 2018: 215,000 tests completed during the quarter; Exact and Pfizer enter into a marketing agreement for Cologuard. Exact CEO Kevin Conroy has pointed to this partnership as a driver of Exact’s success to date. The completion figures that follow support that.
October 2018: 241,000 tests completed during the quarter
February 2019: 292,000 tests completed during the quarter; 934,000 completed in 2018. Exact surpasses 2 million completed tests.
April 2019: 334,000 tests completed during the quarter
June 2019: Exact opens a new laboratory in Madison to expand testing capabilities.
July 2019: 415,000 tests completed; Exact announces $2.8 billion Genomic Health acquisition
September 2019: Exact receives expanded FDA approval to screen patients between ages 45 and 49.
October 2019: 456,000 tests completed during the quarter; Exact launches a seven-year, 150,000-patient study to evaluate Cologuard
November 2019: Exact completes Genomic Health acquisition
February 2020: 477,000 tests completed in the quarter; 1.68 million in 2019
More articles on surgery centers:
The evolution of ASCs in 50 years + what the future holds: 6 industry leaders’ thoughts
The joint-venture model for cardiovascular ASCs: 3 advantages
4 barriers to cardiology in ASCs
